Navigation Links
Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
Date:8/7/2014

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the second quarter ended June 30, 2014.

"We are making progress with the FDA discussing the alternatives for the post-marketing obligation for evaluation of cardiovascular outcomes, and we are confident that we can reach agreement on these final details of the NB32 review," said Michael Narachi, CEO of Orexigen.

 

Financial results for the three months ended June 30, 2014
For the three months ended June 30, 2014, Orexigen reported a net loss of $24.5 million, or $0.21 per share, as compared to a net loss of $18.2 million, or $0.19 per share, for the second quarter of 2013.

Total operating expenses for the second quarter of 2014 were $23.7 million compared to $19.1 million for the second quarter of 2013. This overall increase in operating expenses reflects an increase in raw materials, inventory, and manufacturing-related expenses and in stock based compensation expense. While Orexigen is responsible for manufacturing NB32, Takeda Pharmaceuticals will reimburse Orexigen for manufacturing related costs, including finished goods.

As of June 30, 2014, Orexigen had $31.1 million in cash and cash equivalents and an additional $102.2 million in marketable securities, for a total of $133.3 million. Orexigen is eligible to receive cash milestone payments of $100 million from Takeda Pharmaceuticals, between US approval and first commercial sale of NB32.

NB32 program update:

  • NB32 (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR), an investigational medicine for weight loss and the maintenance of weight loss: In June 2014, the United States Food and Drug Administration (FDA) extended it
    '/>"/>

  • SOURCE Orexigen Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
    2. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
    3. Orexigen Resubmits Contrave New Drug Application
    4. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
    5. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    6. Orexigen Announces Successful Interim Analysis of Contrave Light Study
    7. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
    8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    9. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
    10. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    11. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... YORK , Sept. 18, 2014 This BCC Research ... share of major players, market growth and size, and opportunities ... trends and revenue through 2018. Patent analysis in the report ... as the U.S., Europe and ... to: - Define and discuss the global medical device technologies ...
    (Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
    (Date:9/18/2014)... 2014  ADM Tronics Unlimited, Inc. (OTCQB: ADMT) ... its corporate Advisory Board for business development. ... Harvard Medical School and Visiting Professor at the ... Masters degree in Electronics Engineering and his Ph.D. ... Bologna. After spending a year as a visiting ...
    Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
    ... ADDISON, Texas, March 11, 2011 U LURUInc.(NYSE ... the development of a portfolio of wound management and oral ... NYSE Amex LLC (the "Exchange") advising ULURU that it is ... continued listing standards under Section 1003 of the Exchange,s Company ...
    ... (Nasdaq: NVAX ), a clinical-stage vaccine company, announced ... be presenting at the ROTH 23rd Annual OC Growth Stock ... at The Ritz Carlton, Laguna Niguel, CA.  A live audio-only ... Company website at www.novavax.com under Investors/Events, and a ...
    Cached Medicine Technology:ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex 2
    (Date:9/19/2014)... 19, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Potassium Chloride . , ... recalled one lot of Potassium Chloride Injection 10mEq ... cartons. Potassium Chloride, administered intravenously, is used to treat potassium ... on a labeling error on the shipping cartons in a ...
    (Date:9/19/2014)... Yisrayl Hawkins, Pastor of The House of ... need to protect children. He begins by encouraging the reader ... reminds that there are many other children, like Michael Brown, ... spreading faster than cancer all over the world and must ... to seven billion Michaels in the world who were left ...
    (Date:9/19/2014)... VogueQueen.com has recently unveiled a ... ladies more beautiful at their weddings. The new range ... The company’s new products are made for the coming ... for all the global clients. , “The ... have ordered several items on its website. I'm very ...
    (Date:9/18/2014)... (PRWEB) September 18, 2014 Defendants ... http://www.xareltolawsuitcenter.com ) currently pending in Pennsylvania’s Philadelphia Court ... claims filed on behalf of out-of-state plaintiffs dismissed, ... on September 11th, the defendants maintain that circumstances ... in the lawsuits have no connection to Pennsylvania. ...
    (Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
    Breaking Medicine News(10 mins):Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
    ... , 221.10.254.64 (Garrison, NY) Concern about the capacity ... studies has largely focused on impairment due to psychotic ... given to the cognitive errors that prospective participants make ... In a study reported in IRB: ...
    ... HealthDay Reporter , MONDAY, Aug. 8 (HealthDay ... say that elderly lung cancer patients can gain significant ... in younger patients. The finding raises questions about ... American Society of Clinical Oncology in 2004, which advised ...
    ... There are increasing pressures for health care providers ... policy making. But Canadians are more likely to allow ... that their privacy is protected. A new report by ... Electronic Health Information at the University of Ottawa and ...
    ... Aug. 8 (HealthDay News) -- One reason why people worldwide ... be because the games allow them to "try on" characteristics ... The research included hundreds of casual game players and nearly ... for playing, as well as their post-game emotions. The ...
    ... HealthDay Reporter , MONDAY, Aug. 8 (HealthDay News) -- At ... diagnose heart disease is found to have major blockages requiring ... few are found to have a major blockage when undergoing ... procedures, according to a study in the Aug. 16 issue ...
    ... published in the August issue of the Journal of ... in the number of laparoscopic bariatric procedures, an increase in ... mortality rates between 2003 and 2008. During the past decade, ... authors concluded that these trends are due, in part, to ...
    Cached Medicine News:Health News:Schizophrenia study finds cognitive deficits significantly impair decision-making capacity 2Health News:Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study 2Health News:Elderly Lung Cancer Patients Can Gain From Two-Drug Chemo: Study 3Health News:Most Canadians can be uniquely identified from their date of birth and postal code 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 2Health News:Hospitals Vary Widely in Rate of Heart Procedures: Study 3Health News:Number of laparoscopic bariatric procedures continued to rise between 2003-2008 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: